LEO Pharma to present at the 44th annual J.P. Morgan Healthcare Conference
7.1.2026 13:00:00 CET | LEO Pharma | Pressemeddelelse
Ballerup, Denmark, January 7, 2026 – LEO Pharma, a global leader in medical dermatology, announced today that CEO Christophe Bourdon will deliver a company update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 9:00 AM PST.
With over 60 years of specialist expertise in medical dermatology and more than 90 million patients served in 70+ markets, LEO Pharma is uniquely positioned in one of healthcare’s most attractive and underserved sectors. Backed by an unmatched portfolio combining category‑leading brands with first‑in‑class innovations, the company is redefining standards of care for patients with high unmet needs.
Entering 2026, LEO Pharma builds on the strong momentum of recent years, marked by robust top-line growth, significant margin expansion, and a promising pipeline. Leveraging its unique global platform, the LEO Pharma is advancing innovation as the preferred partner in medical dermatology.
The J.P. Morgan Healthcare Conference presentation will provide investors, analysts, and partners with insights into LEO Pharma’s innovation strategy, growth momentum, and global ambitions in medical dermatology. Attendees can expect a high‑energy session that spotlights the company’s differentiated market position and outlines its next chapter of industry leadership.
Event details:
📍 Westin St. Francis Hotel, San Francisco
📅 Tuesday, January 13, 2026
🕘 9:00 AM PST
Kontakter
Jeppe IlkjærGlobal Communications
Tlf:+45 3050 2014JEILK@leo-pharma.comAbout LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. Together, we reach far beyond the skin.
For more information, visit www.leo-pharma.com.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma delivers 10% revenue growth at CER and strengthens late-stage pipeline18.8.2026 09:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 18 August, 2026 – In H1 2026, LEO Pharma delivered strong revenue growth, driven by the dermatology portfolio, with an improved gross margin alongside significantly increased investments in commercial and innovation activities. In August, LEO Pharma agreed to acquire the global rights for dersimelagon, an investigational first-in-class oral therapy with potential launch in 2027. Together with the acquisition of Replay, announced in April 2026, the agreement further strengthens LEO Pharma’s pipeline in rare genetic skin diseases. Financial highlights LEO Pharma’s revenue increased by 7% to DKK 7,257 million, and by 10% at constant exchange rates (CER). The revenue growth was led by North America (38% at CER) and Rest of World (10% at CER), while sales in Europe (0% at CER) were broadly stable compared to H1 2025. Revenue from the Dermatology portfolio grew by 12% (CER), driven by the strategic brands Anzupgo®, Spevigo® and Adtralza®/Adbry®, which combined had a revenu
LEO Pharma further strengthens late-stage pipeline with the acquisition of dersimelagon18.8.2026 08:58:00 CEST | Pressemeddelelse
Acquisition adds dersimelagon to LEO Pharma’s rare dermatology pipeline, an investigational once-daily oral melanocortin 1 receptor (MC1R) agonist for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) that has completed Phase 3 development and for which a New Drug Application (NDA) has been submitted to U.S. Food and Drug Administration (FDA) for review in June 2026.1 Leverages LEO Pharma's six decades of dermatology expertise to advance innovation for patients with rare skin diseases through the addition of this oral late-stage asset, building on LEO Pharma’s recent acquisition of Replay and partnership with Boehringer Ingelheim for Spevigo® (spesolimab). EPP and XLP are rare, devastating lifelong genetic disorders that cause severe sunlight-induced skin pain, as well as rash, swelling, redness, burning sensations and, in some cases, liver damage.2,3 Under the terms of the agreement, LEO Pharma will acquire worldwide rights to dersimelagon from Tanabe Pharma for up
LEO Pharma elects Henriette Mersebach to the Board of Directors14.8.2026 09:00:00 CEST | Pressemeddelelse
Henriette Mersebach will bring deep pharmaceutical R&D and innovation expertise to the Board
LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis9.7.2026 17:00:00 CEST | Pressemeddelelse
TRAPEDS-1 is a Phase 2 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.1 The pharmacokinetic profile was as expected and consistent with what has previously been observed with tralokinumab. Tralokinumab was generally well tolerated for up to 172 weeks of treatment, with no new safety signals identified.
LEO Pharma to showcase new data highlighting the burden and unmet needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen25.6.2026 13:00:00 CEST | Pressemeddelelse
New data show that chronic hand eczema can disrupt working lives and school days, with many patients reporting sick leave from work and worsening of symptoms during everyday activities.1 Findings from the DELTA FORCE and DELTA TEEN phase 3 studies highlight the heavy burden of chronic hand eczema across the life course – from impaired work productivity in adults to an impact on school life in adolescents.1,2
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum